ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to … Read more
Market Cap & Net Worth: ALPHAHELIX MOL.DIAGN. SK1 (4MB)
ALPHAHELIX MOL.DIAGN. SK1 (F:4MB) has a market capitalization of $1.54 Million (€1.50 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #36765 globally and #4580 in its home market, demonstrating a -26.67% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALPHAHELIX MOL.DIAGN. SK1's stock price €0.02 by its total outstanding shares 68398899 (68.40 Million).
ALPHAHELIX MOL.DIAGN. SK1 Market Cap History: 2021 to 2026
ALPHAHELIX MOL.DIAGN. SK1's market capitalization history from 2021 to 2026. Data shows change from $16.08 Million to $1.54 Million (-33.35% CAGR).
ALPHAHELIX MOL.DIAGN. SK1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALPHAHELIX MOL.DIAGN. SK1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4MB by Market Capitalization
Companies near ALPHAHELIX MOL.DIAGN. SK1 in the global market cap rankings as of March 19, 2026.
Key companies related to ALPHAHELIX MOL.DIAGN. SK1 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
ALPHAHELIX MOL.DIAGN. SK1 Historical Marketcap From 2021 to 2026
Between 2021 and today, ALPHAHELIX MOL.DIAGN. SK1's market cap moved from $16.08 Million to $ 1.54 Million, with a yearly change of -33.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.54 Million | +25.71% |
| 2025 | €1.23 Million | +25.00% |
| 2024 | €982.93K | -56.79% |
| 2023 | €2.27 Million | -32.22% |
| 2022 | €3.36 Million | -79.13% |
| 2021 | €16.08 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ALPHAHELIX MOL.DIAGN. SK1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.54 Million USD |
| MoneyControl | $1.54 Million USD |
| MarketWatch | $1.54 Million USD |
| marketcap.company | $1.54 Million USD |
| Reuters | $1.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.